| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Polydatin (Reservatrol 3-β-mono-D-Glucoside; Piceid) is a naturally occuring stilbene and a precursor of resveratrol as well as a crystal component extracted from the root stem of perennial herbage Polygonum Cuspidatum Sieb.et Zucc. It is also known as a PLA2 inhibitor which reduces Phospholipase A2 (PLA2) activity and sPLA2-IIA mRNA expression and mitigates LPS-induced lung injury by increasing increased Clara cell secretory protein (CCSP) expression.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
BMC Cell Biol.2011 Jul 25;12:31;Mediators Inflamm.2013;2013:354087.
|
||
| Additional Infomation |
Trans-piceid is a stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue. It has a role as a metabolite, a potassium channel modulator, an anti-arrhythmia drug, a hepatoprotective agent, an antioxidant, a nephroprotective agent and a geroprotector. It is a stilbenoid, a polyphenol, a beta-D-glucoside and a monosaccharide derivative. It is functionally related to a trans-resveratrol.
Polydatin, or Piceid, is a natural precursor and glycoside form of resveratrol with a monocrystalline structure. While it is isolated from the bark of *Picea sitchensis* or *Polygonum cuspidatum*, polydatin may be detected in grape, peanut, hop cones, red wines, hop pellets, cocoa-containing products, chocolate products and many daily diets. Polydatin possesses anti-inflammatory, immunoregulatory, anti-oxidative and anti-tumor activities. It is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis. Polydatin has been reported in Humulus lupulus, Veratrum dahuricum, and other organisms with data available. |
| Molecular Formula |
C20H22O8
|
|
|---|---|---|
| Molecular Weight |
390.38
|
|
| Exact Mass |
407.134
|
|
| CAS # |
65914-17-2
|
|
| Related CAS # |
|
|
| PubChem CID |
5281718
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.521 g/cm3
|
|
| Boiling Point |
707.7ºC at 760 mmHg
|
|
| Melting Point |
223-226 °C(lit.)
|
|
| Flash Point |
381.8ºC
|
|
| LogP |
0.496
|
|
| Hydrogen Bond Donor Count |
6
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
28
|
|
| Complexity |
506
|
|
| Defined Atom Stereocenter Count |
5
|
|
| SMILES |
C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O
|
|
| InChi Key |
HSTZMXCBWJGKHG-CUYWLFDKSA-N
|
|
| InChi Code |
InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1
|
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5616 mL | 12.8080 mL | 25.6161 mL | |
| 5 mM | 0.5123 mL | 2.5616 mL | 5.1232 mL | |
| 10 mM | 0.2562 mL | 1.2808 mL | 2.5616 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05867693 | Recruiting | Dietary Supplement: palmithoylethanolamide/polydatin |
Irritable Bowel Syndrome | University of Roma La Sapienza | April 19, 2023 | Not Applicable |
| NCT02372903 | Completed | Drug: Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin |
Endometriosis Chronic Pelvic Pain |
University of Cagliari | October 2013 | Not Applicable |
| NCT04912947 | Completed | Dietary Supplement: Immusystem Other: Placebo |
Oxidative Stress | Complife Italia Srl | October 30, 2020 | Not Applicable |
|
|---|
|
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
